Ocrelizumab (2) – Ocrevus®

Relapsing-remitting multiple sclerosis, aged ≥ 10 to < 18 years

Characteristics

Start date 15.11.2026
Resolution 05.05.2027 – active procedure
INN Ocrelizumab
Brand name Ocrevus®
Pharm. company Roche Pharma AG
G-BA Procedure ID D-1401
Therapeutic area n.d.
Reason for procedure New therapeutic indication

Associated procedures

Ocrelizumab (2) Ocrevus® Roche Pharma AG n.d. Relapsing-remitting multiple sclerosis, aged ≥ 10 to < 18 years n.d. active procedure
Ocrelizumab (1) Ocrevus® Roche Pharma AG Nervous system diseases Multiple sclerosis (MS) 165,300–182,200 81% Proof of minor additional benefit


<< List of all resolutions